Search

everythinglearnresearchcommunity

for

Search:↓

Boosting certain cell signals can prevent hair loss from chemotherapy and radiation.

About half the patients treated with capecitabine and docetaxel developed severe hand-foot syndrome.

WNT activation in scalp fibroblasts boosts hair growth by increasing FGF9.

Espumil foam base allows easy preparation of skin medications for hairy areas.

Sonidegib often causes hair loss, and LC-OCT helps identify early signs.

The FFA-QLI is a reliable tool for assessing quality of life in women with severe Frontal Fibrosing Alopecia.

Treatments for Frontal Fibrosing Alopecia have not been proven effective.

Infliximab can cause SAPHO syndrome, which may improve with Spesolimab and methotrexate.

Editing the FGF5 gene in sheep increases fine wool growth.

Pentoxifylline helps hair regrowth in rats with hair loss.

KLF4 is important for keeping hair follicle stem cells inactive.

Two women had skin reactions from a hair loss treatment and got better after stopping use.

Combining plasma rich in growth factors with hair transplant surgery may lead to faster recovery and better outcomes for hair loss treatment.

PEGL-DOX causes Hand-Foot Syndrome due to skin reactions from prolonged circulation and ROS generation.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.

The new skin cream with FOL-005 safely promotes hair growth and is stable and user-friendly.

Ruxolitinib can cause a delayed skin reaction on the nose.

Spanlastic nanovesicles can improve efinaconazole delivery through nails.

Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.

Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.

Adriamycin and ifosfamide together work best for advanced soft tissue sarcomas.

Topical tofacitinib shows promise as a future treatment for alopecia areata.